Leading NoSQL Database Powers Genomic Data Analysis at Unprecedented Performance, Price and Scalability
NEW YORK—October 22, 2013—MongoDB today announced that Seven Bridges Genomics, a biotech company based in Cambridge, Mass., and Belgrade, Serbia, selected MongoDB to power data analytics for its next-generation sequencing (NGS) analysis platform. MongoDB enables researchers to collaboratively perform high-throughput genomic sequencing.
The cloud-based Seven Bridges platform offers a one-stop solution for managing NGS projects, enabling users to intuitively construct and run complex analysis pipelines for genomic data, easily transfer data between tools and securely share results. Seven Bridges relies on MongoDB as a core part of its infrastructure to store complex, contextually rich metadata for genomics pipelines and to collect statistics from distributed computation resources.
The Seven Bridges Platform, which runs on Amazon Web Services (AWS), has been publicly available since February 2012 and recently won BioIT World’s Best of Show recognition. It is currently employed by independent researchers, pharmaceutical and biotechnology firms, as well as academic institutions, including the Harvard Department of Stem Cell and Regenerative Biology and the Cancer Genomics Research Laboratory at the National Cancer Institute.
“Seven Bridges simplifies data analysis for genomics by eliminating the need to manage large-scale computation and storage infrastructures that are expensive to maintain and scale,” said Igor Bogicevic, co-founder and CTO of Seven Bridges Genomics. “MongoDB supports our long-term requirements for scalability and it allows us to quickly add features, without forcing us to re-think our model and architecture or invest heavily in re-engineering our infrastructure.”
Seven Bridges turned to MongoDB for its flexible document model, simple integration and maintenance, and ability to deliver performance and stability in production. With MongoDB, Seven Bridges can store and analyze statistical data to optimize computational resources, while delivering an easy-to-use platform for researchers to analyze massive data sets.
“The volume and velocity of data are critical to genome projects, where researchers must reproduce and efficiently manage life-saving medical breakthroughs,” said Max Schireson, CEO at MongoDB. “For Seven Bridges Genomics, MongoDB delivers on its promise of high performance and flexibility, offering a NoSQL data store that reliably scales to meet skyrocketing data demand.”
MongoDB has a thriving open source global community with more than 5 million downloads, 100,000 online education registrations, 20,000 user group members and 20,000 MongoDB Days attendees.
Thousands of organizations have chosen the MongoDB document-oriented database due to its agile and scalable approach. Common use cases include operational and analytical big data, content management and delivery, mobile and social infrastructure, user data management and data hub.
About MongoDB, Inc. MongoDB (from humongous) is reinventing data management and powering big data as the leading NoSQL database. Designed for how we build and run applications today, MongoDB empowers organizations to be more agile and scalable. It enables new types of applications, better customer experience, faster time to market and lower costs. To learn more, please visit www.mongodb.com.